Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma.

about

Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma.

Item

http://www.wikidata.org/entity/Q50192132

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Detection of EGFR and BRAF mut ...... action in lung adenocarcinoma.

@en

Detection of EGFR and BRAF mut ...... action in lung adenocarcinoma.

@nl

type

Item

label

Detection of EGFR and BRAF mut ...... action in lung adenocarcinoma.

@en

Detection of EGFR and BRAF mut ...... action in lung adenocarcinoma.

@nl

prefLabel

Detection of EGFR and BRAF mut ...... action in lung adenocarcinoma.

@en

Detection of EGFR and BRAF mut ...... action in lung adenocarcinoma.

@nl

P1476

Detection of EGFR and BRAF mut ...... action in lung adenocarcinoma.

@en

P2093

Baorui Liu

http://www.w3.org/2001/XMLSchema#string

Hang Zhang

http://www.w3.org/2001/XMLSchema#string

Lifeng Wang

http://www.w3.org/2001/XMLSchema#string

Lixia Yu

http://www.w3.org/2001/XMLSchema#string

Rutian Li

http://www.w3.org/2001/XMLSchema#string

Xiaoyan Shen

http://www.w3.org/2001/XMLSchema#string

Yang Yang

http://www.w3.org/2001/XMLSchema#string

Yi Meng

http://www.w3.org/2001/XMLSchema#string

P2860

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Global cancer statistics, 2012

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

P304

3295-3304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2017.7652

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29467863

http://www.w3.org/2001/XMLSchema#string

P932

5778904

http://www.w3.org/2001/XMLSchema#string